lori_vegas said:

Reading about receptor desensitisation and trying to work out which of the effects adapt over time and which do not, because people clearly experience…

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
2. Arg34 substitution: improved chemical stability
3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

LibrarianMeg said:

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).

That is correct as far as it goes, and here is where it stops going. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Ask again with the specifics and you will get a better answer than this one.

lori_vegas said:

Reading about receptor desensitisation and trying to work out which of the effects adapt over time and which do not, because people clearly experience…

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

Adding the clinical framing, because it changes how the question reads.

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

• Tmax: 24-72 hours post-injection
• T½: ~168 hours (7 days) — enables weekly dosing
• Steady state: reached at 4-5 weeks
• Bioavailability (SubQ): ~89%
• Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.